AI-enhanced clinical trial-in-a-dish platform for improved DILI risk classification and mechanistic insights into hepatotoxicity
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
A new in vitro rat liver platform capturing biological diversity for drug-induced liver injury assessment and reduction of animal use in drug discovery and development
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
PredictCan Presents Its DILI Platform at the 3RsC & IQ Consortium Liver MPS Webinar
PredictCan CTO Dr. Sara Cherradi presented the company’s individual-centric DILI platform during the “Revisiting Liver MPS” webinar organized as part of the 3Rs Collaborative and IQ Consortium Webinar Series.
New Study Introduces an Individual-Centric In Vitro–In Vivo Strategy for DILI Assessment
In collaboration with PRADO, PredictCan developed serum-derived educated rat liver spheroids that enable individualized in vitro and in vivo DILI assessment within the same animal, providing richer toxicity data while supporting a substantial reduction in animal use.
New Study Demonstrates PredictCan’s Individual-Centric Approach to DILI Prediction
Published in Frontiers in Toxicology in collaboration with Centre Antoine Lacassagne, the study demonstrates how PredictCan’s human serum-derived liver models combined with AI can capture chronic and individual-specific DILI while providing clinically relevant risk classification and mechanistic insights.
PredictCan Extends Its Cell Educating Technology™ to Pancreatic Cancer
A new study published in Translational Oncology, in collaboration with clinicians from Montpellier University Hospital, demonstrates the application of PredictCan’s patient-educated models to pancreatic cancer and their ability to reflect individual clinical treatment responses.
PredictCan’s HCC Models Predict Individual Clinical Response to Anticancer Therapies
Published in Scientific Reports, PredictCan’s patient-centric HCC models correctly predicted 34 out of 37 clinical treatment outcomes, demonstrating the potential of combining human biological diversity with the TICK exclusion strategy for preclinical anticancer drug evaluation.
Using individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
sing individual-centric model to detect immune-mediated idiosyncratic drug-induced liver injury at preclinical stage
Dissecting the idiosyncratic drug-induced liver injury (iDILI)-initiating mechanism using the individual-centric model: the role of the innate immune response
Uncovering the mechanism of troglitazone-mediated idiosyncratic drug-induced liver injury with individual-centric models
